These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

113 related items for PubMed ID: 11692156

  • 1. Bcl-2 antisense oligonucleotides chemosensitize human gastric cancer in a SCID mouse xenotransplantation model.
    Wacheck V, Heere-Ress E, Halaschek-Wiener J, Lucas T, Meyer H, Eichler HG, Jansen B.
    J Mol Med (Berl); 2001 Oct; 79(10):587-93. PubMed ID: 11692156
    [Abstract] [Full Text] [Related]

  • 2. Bcl-2 antisense (G3139, Genasense) enhances the in vitro and in vivo response of Epstein-Barr virus-associated lymphoproliferative disease to rituximab.
    Loomis R, Carbone R, Reiss M, Lacy J.
    Clin Cancer Res; 2003 May; 9(5):1931-9. PubMed ID: 12738752
    [Abstract] [Full Text] [Related]

  • 3. Preclinical evaluation of antisense bcl-2 as a chemosensitizer for patients with gastric carcinoma.
    Kim R, Emi M, Tanabe K, Toge T.
    Cancer; 2004 Nov 15; 101(10):2177-86. PubMed ID: 15476281
    [Abstract] [Full Text] [Related]

  • 4. Bcl-2 antisense oligonucleotides are effective against systemic but not central nervous system disease in severe combined immunodeficient mice bearing human t(14;18) follicular lymphoma.
    Mohammad R, Abubakr Y, Dan M, Aboukameel A, Chow C, Mohamed A, Hamdy N, Al-Katib A.
    Clin Cancer Res; 2002 Apr 15; 8(4):1277-83. PubMed ID: 11948143
    [Abstract] [Full Text] [Related]

  • 5. Molecular and pharmacokinetic properties associated with the therapeutics of bcl-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin.
    Lopes de Menezes DE, Hudon N, McIntosh N, Mayer LD.
    Clin Cancer Res; 2000 Jul 15; 6(7):2891-902. PubMed ID: 10914739
    [Abstract] [Full Text] [Related]

  • 6. Combined blockade of protein kinase A and bcl-2 by antisense strategy induces apoptosis and inhibits tumor growth and angiogenesis.
    Tortora G, Caputo R, Damiano V, Bianco R, Fontanini G, Cuccato S, De Placido S, Bianco AR, Ciardiello F.
    Clin Cancer Res; 2001 Aug 15; 7(8):2537-44. PubMed ID: 11489837
    [Abstract] [Full Text] [Related]

  • 7. Mcl-1 is a novel therapeutic target for human sarcoma: synergistic inhibition of human sarcoma xenotransplants by a combination of mcl-1 antisense oligonucleotides with low-dose cyclophosphamide.
    Thallinger C, Wolschek MF, Maierhofer H, Skvara H, Pehamberger H, Monia BP, Jansen B, Wacheck V, Selzer E.
    Clin Cancer Res; 2004 Jun 15; 10(12 Pt 1):4185-91. PubMed ID: 15217956
    [Abstract] [Full Text] [Related]

  • 8. Antitumor efficacy of oblimersen Bcl-2 antisense oligonucleotide alone and in combination with vinorelbine in xenograft models of human non-small cell lung cancer.
    Hu Y, Bebb G, Tan S, Ng R, Yan H, Sartor JR, Mayer LD, Bally MB.
    Clin Cancer Res; 2004 Nov 15; 10(22):7662-70. PubMed ID: 15569999
    [Abstract] [Full Text] [Related]

  • 9. Bcl-2 antisense oligonucleotides (G3139) inhibit Merkel cell carcinoma growth in SCID mice.
    Schlagbauer-Wadl H, Klosner G, Heere-Ress E, Waltering S, Moll I, Wolff K, Pehamberger H, Jansen B.
    J Invest Dermatol; 2000 Apr 15; 114(4):725-30. PubMed ID: 10733680
    [Abstract] [Full Text] [Related]

  • 10. Bcl-2 protein in 518A2 melanoma cells in vivo and in vitro.
    Benimetskaya L, Ayyanar K, Kornblum N, Castanotto D, Rossi J, Wu S, Lai J, Brown BD, Popova N, Miller P, McMicken H, Chen Y, Stein CA.
    Clin Cancer Res; 2006 Aug 15; 12(16):4940-8. PubMed ID: 16914583
    [Abstract] [Full Text] [Related]

  • 11. [Bcl-2 antisense oligodeoxyribonucleotide increases apoptosis of lung carcinoma cells induced by cisplatin].
    Ouyang N, Ran P, Qiu Z.
    Zhonghua Jie He He Hu Xi Za Zhi; 2000 Dec 15; 23(12):722-4. PubMed ID: 11778475
    [Abstract] [Full Text] [Related]

  • 12. Modulation of apoptosis by endogenous Bcl-xL expression in MKN-45 human gastric cancer cells.
    Kondo S, Shinomura Y, Kanayama S, Higashimoto Y, Kiyohara T, Zushi S, Kitamura S, Ueyama H, Matsuzawa Y.
    Oncogene; 1998 Nov 19; 17(20):2585-91. PubMed ID: 9840921
    [Abstract] [Full Text] [Related]

  • 13. Antitumor effect of G3139 Bcl-2 antisense oligonucleotide is independent of its immune stimulation by CpG motifs in SCID mice.
    Wacheck V, Krepler C, Strommer S, Heere-Ress E, Klem R, Pehamberger H, Eichler HG, Jansen B.
    Antisense Nucleic Acid Drug Dev; 2002 Dec 19; 12(6):359-67. PubMed ID: 12568310
    [Abstract] [Full Text] [Related]

  • 14. Tumor regression by combination antisense therapy against Plk1 and Bcl-2.
    Elez R, Piiper A, Kronenberger B, Kock M, Brendel M, Hermann E, Pliquett U, Neumann E, Zeuzem S.
    Oncogene; 2003 Jan 09; 22(1):69-80. PubMed ID: 12527909
    [Abstract] [Full Text] [Related]

  • 15. Mechanism(s) of antitumor action in protracted infusion of low dose 5-fluorouracil and cisplatin in gastric carcinoma.
    Kim R, Tanabe K, Inoue H, Toge T.
    Int J Oncol; 2002 Mar 09; 20(3):549-55. PubMed ID: 11836567
    [Abstract] [Full Text] [Related]

  • 16. CpG immunomer DNA enhances antisense protein kinase A RIalpha inhibition of multidrug-resistant colon carcinoma growth in nude mice: molecular basis for combinatorial therapy.
    Nesterova MV, Johnson NR, Stewart T, Abrams S, Cho-Chung YS.
    Clin Cancer Res; 2005 Aug 15; 11(16):5950-5. PubMed ID: 16115938
    [Abstract] [Full Text] [Related]

  • 17. [Effects of CPUY013, a novel Topo I inhibitor, on human gastric adenocarcinoma BGC823 cells in vitro and in vivo].
    Ji YB, Zhou JH, Zuo MX, You QD.
    Yao Xue Xue Bao; 2008 Aug 15; 43(8):811-8. PubMed ID: 18956773
    [Abstract] [Full Text] [Related]

  • 18. RhoGDI2 confers gastric cancer cells resistance against cisplatin-induced apoptosis by upregulation of Bcl-2 expression.
    Cho HJ, Baek KE, Park SM, Kim IK, Nam IK, Choi YL, Park SH, Im MJ, Choi J, Ryu J, Kim JW, Lee CW, Kang SS, Yoo J.
    Cancer Lett; 2011 Dec 01; 311(1):48-56. PubMed ID: 21752536
    [Abstract] [Full Text] [Related]

  • 19. Combination bcl-2 antisense and radiation therapy for nasopharyngeal cancer.
    Yip KW, Mocanu JD, Au PY, Sleep GT, Huang D, Busson P, Yeh WC, Gilbert R, O'Sullivan B, Gullane P, Bastianutto C, Liu FF.
    Clin Cancer Res; 2005 Nov 15; 11(22):8131-44. PubMed ID: 16299246
    [Abstract] [Full Text] [Related]

  • 20. Inhibition of bcl-2 enhances the efficacy of chemotherapy in renal cell carcinoma.
    Kausch I, Jiang H, Thode B, Doehn C, Krüger S, Jocham D.
    Eur Urol; 2005 May 15; 47(5):703-9. PubMed ID: 15826766
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.